{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:12:49Z","timestamp":1788959569962,"version":"build-2803163510"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    With over 10 million new cases and 1.6 million deaths annually, tuberculosis (TB) continues to be a significant worldwide health-burden. To assist in curbing the spread of TB, the century-old BCG, which is a live-attenuated vaccine, is now the only licensed TB vaccine used in humans. However, BCG\u2019s limited efficacy and poor antigenicity in adults have evoked the need to design new vaccines against TB. The limited parameter is the availability of potent antigens; as a consequence, it is imperative to study the\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    (\n                    <jats:italic>Mtb<\/jats:italic>\n                    )-specific antigens that can provide a stronger immune response if included in vaccine candidates. Through this review, we aim to concentrate on the progress of current vaccine-candidates undergoing preclinical and clinical-studies. Moreover, it is not the pathogen but the genetics of the host that plays an essential role in fine tuning the immune-response and susceptibility to TB. Over the past 50 years, a systematic approach to treating TB patients has overlooked factors like pharmacokinetics, immune-response, and treatment duration. Henceforth, this review highlights the precision medicine-guided approach considering genetic makeup and host immunity that could influence clinical management choices. The consolidated review will shed light on advancements in vaccine-candidates, which can be harnessed in prophylactic development against TB.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1608104","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:29:27Z","timestamp":1753853367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["BCG and beyond: unlocking new frontiers in TB vaccine development"],"prefix":"10.3389","volume":"16","author":[{"given":"Aishwarya","family":"Shaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akanksha","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashima","family":"Bhaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ved Prakash","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"B1","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed"},{"key":"B2","article-title":"The history of tuberculosis: from the first historical records to the isolation of Koch\u2019s bacillus","volume":"58","author":"Barberis","year":"2017","journal-title":"J Prev Med Hyg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2011.14","article-title":"Macrophages and control of granulomatous inflammation in tuberculosis","volume":"4","author":"Flynn","year":"2011","journal-title":"Mucosal Immunol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.3390\/ijms24065202","article-title":"Tuberculosis: pathogenesis, current treatment regimens and new drug targets","volume":"24","author":"Jellinger","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0835","article-title":"Global tuberculosis targets and milestones set for 2016-2035: Definition and rationale","volume":"22","author":"Floyd","year":"2018","journal-title":"Int J Tuberculosis Lung Disease."},{"key":"B6","first-page":"303","volume-title":"Global tuberculosis report 2013","year":"2013"},{"key":"B7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.prrv.2020.08.004","article-title":"Bacille Calmette Gu\u00e9rin (BCG) and new TB vaccines: Specific, cross-mycobacterial and off-target effects","volume":"36","author":"Fritschi","year":"2020","journal-title":"Paediatr Respir Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.959656","article-title":"A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19","volume":"13","author":"Singh","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"778028","DOI":"10.3389\/fimmu.2021.778028","article-title":"A perspective on the success and failure of BCG","volume":"12","author":"Kumar","year":"2021","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41577-019-0174-z","article-title":"Moving tuberculosis vaccines from theory to practice","volume":"19","author":"Andersen","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005206","article-title":"BCG skin infection triggers IL-1R-myD88-dependent migration of epCAMlow CD11bhigh skin dendritic cells to draining lymph node during CD4+ T-cell priming","volume":"11","author":"Bollampalli","year":"2015","journal-title":"PloS Pathog"},{"key":"B12","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3389\/fimmu.2019.02806","article-title":"BCG-induced cross-protection and development of trained immunity: implication for vaccine design","volume":"10","author":"Covi\u00e1n","year":"2019","journal-title":"Front Immunol"},{"key":"B13","first-page":"483","article-title":"What\u2019s new in tuberculosis vaccines","volume":"80","author":"Ginsberg","year":"","journal-title":"Bull World Health Organ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/nyas.14235","article-title":"Vaccine innovations for emerging infectious diseases\u2014a symposium report","volume":"1462","author":"Cable","year":"2020","journal-title":"Ann N Y Acad Sci"},{"key":"B15","first-page":"1","article-title":"Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial","volume":"7","author":"Sharma","year":"2017","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175215","article-title":"Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901","volume":"12","author":"Von Reyn","year":"2017","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.09.134","article-title":"Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI\u00ae","volume":"28","author":"Vilaplana","year":"2010","journal-title":"Vaccine."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089612","article-title":"Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection","volume":"9","author":"Nell","year":"2014","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(15)00435-X","article-title":"afety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: A randomised, double-blind, controlled phase I trial","volume":"3","author":"Spertini","year":"2015","journal-title":"Lancet Respir Med"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(19)30251-6","article-title":"Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial","volume":"7","author":"Tameris","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(21)00309-0","article-title":"BCG re-vaccination in Malawi: 30-year follow-up of a large, randomised, double-blind, placebo-controlled trial","volume":"9","author":"Glynn","year":"2021","journal-title":"Lancet Glob Health"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2412381","article-title":"BCG revaccination for the prevention of mycobacterium tuberculosis infection","volume":"392","author":"Schmidt","year":"2025","journal-title":"New Engl J Med"},{"key":"B23","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1473-3099(23)00818-6","article-title":"Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial","volume":"24","author":"dos Santos","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"","journal-title":"New Engl J Med"},{"key":"B25","doi-asserted-by":"crossref","first-page":"100313","DOI":"10.1016\/j.eclinm.2020.100313","article-title":"A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa","volume":"21","author":"Bekker","year":"2020","journal-title":"EClinicalMedicine."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00439-16","article-title":"Safety and immunogenicity of the recombinant mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa","volume":"24","author":"Loxton","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(22)00222-5","article-title":"Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial","volume":"22","author":"Cotton","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2016.07.005","article-title":"Safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study","volume":"100","author":"Gillard","year":"2016","journal-title":"Tuberculosis."},{"key":"B29","doi-asserted-by":"crossref","first-page":"e2459","DOI":"10.1097\/MD.0000000000002459","article-title":"A randomized, controlled safety, and immunogenicity trial of the M72\/AS01 candidate tuberculosis vaccine in HIV-positive Indian adults","volume":"95","author":"Kumarasamy","year":"2016","journal-title":"Medicine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01 E vaccine to prevent tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"New Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1909953","article-title":"Final analysis of a trial of M72\/AS01 E vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"New Engl J Med"},{"key":"B32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/vaccines7040166","article-title":"First-in-human trials of gamTBvac, a recombinant subunit tuberculosis vaccine candidate: safety and immunogenicity assessment","volume":"7","author":"Vasina","year":"2019","journal-title":"Vaccines"},{"key":"B33","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3390\/vaccines8040652","article-title":"Safety and immunogenicity of the gamTBvac, the recombinant subunit tuberculosis vaccine candidate: A phase II, multi-center, double-blind, randomized, placebo-controlled study","volume":"8","author":"Tkachuk","year":"2020","journal-title":"Vaccines"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.05.036","article-title":"The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial","volume":"33","author":"Geldenhuys","year":"2015","journal-title":"Vaccine."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.01.055","article-title":"Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials","volume":"35","author":"Norrby","year":"2017","journal-title":"Vaccine."},{"key":"B36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-018-0057-5","article-title":"The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial","volume":"3","author":"Coler","year":"2018","journal-title":"NPJ Vaccines"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93\u2008+\u2008GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"Penn-Nicholson","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30319-2","article-title":"Safety and immunogenicity of the adjunct therapeutic vaccine ID93\u2008+\u2008GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"9","author":"Day","year":"2021","journal-title":". Lancet Respir Med"},{"key":"B39","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s40121-023-00806-0","article-title":"Safety and immunogenicity of the ID93\u2009+ GLA-SE tuberculosis vaccine in BCG-vaccinated healthy adults: A randomized, double-blind, placebo-controlled phase 2 trial","volume":"12","author":"Choi","year":"2023","journal-title":"Infect Dis Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.102","article-title":"A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime \u2013 MVA85A boost in healthy UK adults","volume":"38","author":"Wilkie","year":"2020","journal-title":"Vaccine."},{"key":"B41","doi-asserted-by":"publisher","first-page":"106205","DOI":"10.1016\/j.jinf.2024.106205","article-title":"Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route","volume":"89","author":"Audran","year":"2024","journal-title":"J Infection."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(23)00501-7","article-title":"Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial","volume":"24","author":"Wajja","year":"","journal-title":"Lancet Infect Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13245","article-title":"Tuberculosis vaccines: Opportunities and challenges","volume":"23","author":"Zhu","year":"2018","journal-title":"Respirology."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1458806","article-title":"The current status, challenges, and future developments of new tuberculosis vaccines","volume":"14","author":"Gong","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B45","first-page":"55","article-title":"Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties","volume":"11","author":"Talwar","year":"2017","journal-title":"Biologics."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2018.08.008","article-title":"Mycobacterium indicus pranii protein MIP_05962 induces Th1 cell mediated immune response in mice","volume":"308","author":"Sharma","year":"2018","journal-title":"Int J Med Microbiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2016.10.002","article-title":"Mycobacterium indicus pranii as a booster vaccine enhances BCG induced immunity and confers higher protection in animal models of tuberculosis","volume":"101","author":"Saqib","year":"2016","journal-title":"Tuberculosis."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189606","article-title":"Autophagy induction by Mycobacterium indicus pranii promotes Mycobacterium tuberculosis clearance from RAW 264.7 macrophages","volume":"12","author":"Singh","year":"2017","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-019-4679-0","article-title":"Mycobacterium indicus pranii therapy induces tumor regression in MyD88- and TLR2-dependent manner","volume":"12","author":"Kumar","year":"2019","journal-title":"BMC Res Notes"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.02.049","article-title":"Cell wall fraction of Mycobacterium indicus pranii shows potential Th1 adjuvant activity","volume":"70","author":"Saqib","year":"2019","journal-title":"Int Immunopharmacol."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1A0714-361R","article-title":"Mycobacterium indicus pranii induces dendritic cell activation, survival, and Th1\/Th17 polarization potential in a TLR-dependent manner","volume":"97","author":"Kumar","year":"2015","journal-title":"J Leukoc Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.12.025","article-title":"Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis","volume":"26","author":"Katoch","year":"2008","journal-title":"Vaccine."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2005.09.026","article-title":"Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis","volume":"100","author":"Dlugovitzky","year":"2006","journal-title":"Respir Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2006.01.024","article-title":"RUTI: A new chance to shorten the treatment of latent tuberculosis infection","volume":"86","author":"Cardona","year":"2006","journal-title":"Tuberculosis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1240684","DOI":"10.3389\/ftubr.2023.1240684","article-title":"Efficacy of RUTI\u00ae immunotherapy against active tuberculosis in a mouse model challenges the Koch phenomenon","volume":"1","author":"Triccas","year":"2023","journal-title":"Front Tuberculosis."},{"key":"B56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/ng.3704","article-title":"Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages","volume":"48","author":"Stucki","year":"2016","journal-title":"Nat Genet"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.07.051","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M","volume":"31","author":"Arbues","year":"2013","journal-title":"tuberculosis-based Vaccine to enter Clin trials. Vaccine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00262-8","article-title":"MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies","volume":"6","author":"White","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2015.10.010","article-title":"MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice","volume":"96","author":"Aguilo","year":"2016","journal-title":"Tuberculosis."},{"key":"B60","article-title":"Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG\u2019s Protection Against Tuberculosis","volume":"525","author":"Clark","year":"2017","journal-title":"J Infect Dis J Infect Dis \u00ae."},{"key":"B61","doi-asserted-by":"crossref","DOI":"10.1136\/archdischild-2015-310282","article-title":"Non-specific effects of vaccines: plausible and potentially important, but implications uncertain","volume":"102","author":"Pollard","year":"2017","journal-title":"Arch Dis Child."},{"key":"B62","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1136\/bmj.i5170","article-title":"Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review","volume":"355","author":"Higgins","year":"2016","journal-title":"BMJ"},{"key":"B63","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1136\/bmjgh-2021-007462","article-title":"Tracking changes in national BCG vaccination policies and practices using the BCG World Atlas","volume":"7","author":"Lancione","year":"2022","journal-title":"BMJ Glob Health"},{"key":"B64","doi-asserted-by":"crossref","first-page":"325109","DOI":"10.3389\/fimmu.2018.00121","article-title":"Next-generation vaccines based on Bacille Calmette-Gu\u00e9rin","volume":"9","author":"Nieuwenhuizen","year":"2018","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02439","article-title":"Heterologous boost following mycobacterium bovis BCG reduces the late persistent, rather than the early stage of intranasal tuberculosis challenge infection","volume":"9","author":"Wu","year":"2018","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2017.07.005","article-title":"A multistage subunit vaccine effectively protects mice against primary progressive tuberculosis, latency and reactivation","volume":"22","author":"Ma","year":"2017","journal-title":"EBioMedicine."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-024-05683-w","article-title":"Early introduction of IL-10 weakens BCG revaccination\u2019s protection by suppressing CD4+Th1 cell responses","volume":"22","author":"Lei","year":"2024","journal-title":"J Transl Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix834","article-title":"Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed bacille calmette-guerin for infants of human immunodeficiency virus-infected mothers: A phase 2 randomized, controlled trial","volume":"66","author":"Nemes","year":"","journal-title":"Clin Infect Dis"},{"key":"B69","volume-title":"Bacillus calmette-gu\u00e9rin (BCG) revaccination and protection against tuberculosis: A systematic review","author":"Lawrence","year":"2024"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(01)00155-4","article-title":"Recombinant BCG vaccines","volume":"19","author":"Ohara","year":"2001","journal-title":"Vaccine."},{"key":"B71","doi-asserted-by":"crossref","first-page":"292743","DOI":"10.3389\/fimmu.2017.01147","article-title":"The recombinant bacille Calmette-Gu\u00e9rin vaccine VPM1002: Ready for clinical efficacy testing","volume":"8","author":"Nieuwenhuizen","year":"2017","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00679-16","article-title":"Deletion of nuoG from the vaccine candidate Mycobacterium bovis BCG \u0394ureC:: Hly improves protection against tuberculosis","volume":"7","author":"Gengenbacher","year":"2016","journal-title":"mBio."},{"key":"B73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms13894","article-title":"Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy","volume":"7","author":"Griffiths","year":"2016","journal-title":"Nat Commun"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.12.053","article-title":"Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial","volume":"31","author":"Grode","year":"2013","journal-title":"Vaccine."},{"key":"B75","doi-asserted-by":"publisher","first-page":"102425","DOI":"10.1016\/j.tube.2023.102425","article-title":"Non-clinical evaluation of local and systemic immunity induced by different vaccination strategies of the candidate tuberculosis vaccine M72\/AS01","volume":"143","author":"Ouaked","year":"2023","journal-title":"Tuberculosis."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.tbtb2-0004-2015","article-title":"Animal models of tuberculosis: an overview","volume":"4","author":"Williams","year":"2016","journal-title":"Microbiol Spectr."},{"key":"B77","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.3389\/fimmu.2019.02089","article-title":"Immunogenicity and safety of the M72\/AS01E candidate vaccine against tuberculosis: A meta-analysis","volume":"10","author":"Ji","year":"2019","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007643","article-title":"comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates","volume":"15","author":"Rodo","year":"2019","journal-title":"PloS Pathog"},{"key":"B79","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.addr.2015.11.012","article-title":"Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates","volume":"102","author":"Agger","year":"2016","journal-title":"Adv Drug Delivery Rev"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176784","article-title":"Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and Guinea pig TB models","volume":"12","author":"Tkachuk","year":"","journal-title":"PloS One"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"Coler","year":"2011","journal-title":"PloS One"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00458-15","article-title":"Protection and Long-Lived Immunity Induced by the ID93\/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate","volume":"23","author":"Baldwin","year":"2016","journal-title":". Clin Vaccine Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247990","article-title":"Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model","volume":"16","author":"Baldwin","year":"2021","journal-title":"PloS One"},{"key":"B84","unstructured":"GLOBAL TUBERCULOSIS REPORT 2020\n          \n          2020"},{"key":"B85","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.3390\/vaccines10122164","article-title":"The Subunit AEC\/BC02 Vaccine Combined with Antibiotics Provides Protection in Mycobacterium tuberculosis-Infected Guinea Pigs","volume":"10","author":"Guo","year":"2022","journal-title":"Vaccines (Basel)."},{"key":"B86","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/vaccines10050825","article-title":"Therapeutic Effect of Subunit Vaccine AEC\/BC02 on Mycobacterium tuberculosis Post-Chemotherapy Relapse Using a Latent Infection Murine Model","volume":"10","author":"Lu","year":"2022","journal-title":"Vaccines"},{"key":"B87","doi-asserted-by":"publisher","first-page":"102210","DOI":"10.1016\/j.coi.2022.102210","article-title":"Viral vector vaccines","volume":"77","author":"McCann","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1128\/iai.73.6.3814-3816.2005","article-title":"Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in Guinea pigs","volume":"73","author":"Williams","year":"2005","journal-title":"Infect Immun"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005264","article-title":"MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques","volume":"4","author":"Verreck","year":"2009","journal-title":"PloS One"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00287-09","article-title":"Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis","volume":"77","author":"Vordermeier","year":"2009","journal-title":"Infect Immun"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1128\/iai.69.2.681-686.2001","article-title":"Enhanced immunogenicity of CD4+ T-cell responses and protective efficacy of a DNA-modified vaccinia virus ankara prime-boost vaccination regimen for murine tuberculosis","volume":"69","author":"McShane","year":"2001","journal-title":"Infect Immun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1086\/590185","article-title":"Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa","volume":"198","author":"Hawkridge","year":"2008","journal-title":"J Infect Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir195","article-title":"Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants","volume":"203","author":"Scriba","year":"2011","journal-title":"J Infect Dis"},{"key":"B94","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe5938?download=true","article-title":"Understanding COVID-19 vaccine efficacy","volume":"370","author":"Lipsitch","year":"1979","journal-title":"Science"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00084-18?download=true","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27485","article-title":"Host factors and vaccine efficacy: Implications for COVID-19 vaccines","volume":"94","author":"Falahi","year":"2022","journal-title":"J Med Virol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00797-19","article-title":"Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs","volume":"93","author":"Dhakal","year":"2019","journal-title":"J Virol"},{"key":"B100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-023-00621-1","article-title":"Impact of host genetic polymorphisms on response to inactivated influenza vaccine in children","volume":"8","author":"Tsang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1172\/jci167762","article-title":"Host genetic background is a barrier to broadly effective vaccine-mediated protection against tuberculosis","volume":"133","author":"Lai","year":"2023","journal-title":"J Clin Invest."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-012-1660-4","article-title":"Association of polymorphism +874 A\/T of interferon-\u03b3 and susceptibility to the development of tuberculosis: Meta-analysis","volume":"31","author":"De Albuquerque","year":"2012","journal-title":"Eur J Clin Microbiol Infect Diseases."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2006.10.002","article-title":"Interferon-\u03b3 gene+874T\u2013A polymorphism is associated with tuberculosis and gamma interferon response","volume":"87","author":"Sallakci","year":"2007","journal-title":"Tuberculosis."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31816099e6","article-title":"Interferon-gamma Low producer genotype +874 overrepresented in Bacillus Calmette-Guerin nonresponding children","volume":"27","author":"Anuradha","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2164-9-413","article-title":"Novel genome polymorphisms in BCG vaccine strains and impact on efficacy","volume":"9","author":"Leung","year":"2008","journal-title":"BMC Genomics"},{"key":"B106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-13017-8","article-title":"An eQTL variant of ZXDC is associated with IFN-\u03b3 production following Mycobacterium tuberculosis antigen-specific stimulation","volume":"7","author":"Jabot-Hanin","year":"2017","journal-title":"Sci Rep"},{"key":"B107","first-page":"7583","article-title":"Unique role for ATG5 in neutrophil-mediated immunopathology during M","volume":"528","author":"Kimmey","year":"2015","journal-title":"tuberculosis infection. Nat"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0707206105","article-title":"ESCRT factors restrict mycobacterial growth","volume":"105","author":"Philips","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.9.4758","article-title":"Mice lacking myeloid differentiation factor 88 display profound defects in host resistance and immune responses to mycobacterium avium infection not exhibited by toll-like receptor 2 (TLR2)- and TLR4-deficient animals","volume":"171","author":"Feng","year":"2003","journal-title":"J Immunol"},{"key":"B110","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1038\/nature13489","article-title":"Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk","volume":"511","author":"Mayer-Barber","year":"2014","journal-title":"Nature"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103541","article-title":"Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis","volume":"189","author":"Shah","year":"2012","journal-title":"J Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208940","article-title":"Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria","volume":"13","author":"Graustein","year":"2018","journal-title":"PloS One"},{"key":"B113","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201611-2346OC","article-title":"A functional toll-interacting protein variant is associated with bacillus calmette-gu\u00e9rin-specific immune responses and tuberculosis","volume":"196","author":"Shah","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B114","doi-asserted-by":"crossref","first-page":"16085","DOI":"10.1038\/ncomms16085","article-title":"Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis","volume":"8","author":"Aguilo","year":"2017","journal-title":"Nat Commun"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005760","article-title":"A quantitative analysis of complexity of human pathogen-specific CD4 T cell responses in healthy M. tuberculosis infected South Africans","volume":"12","author":"Lindestam Arlehamn","year":"2016","journal-title":"PloS Pathog"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002174","article-title":"Association of human TLR1 and TLR6 deficiency with altered immune responses to BCG vaccination in South African infants","volume":"7","author":"Randhawa","year":"2011","journal-title":"PloS Pathog"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1097\/inf.0000000000001375","article-title":"Association of MBL2, TLR1, TLR2 and TLR6 polymorphisms with production of IFN-\u03b3 and IL-12 in BCG osteitis survivors R1","volume":"36","author":"P\u00f6yh\u00f6nen","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"B118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep15443","article-title":"Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations","volume":"5","author":"Abdallah","year":"2015","journal-title":"Sci Rep"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005614","article-title":"Oral Tolerance to Environmental Mycobacteria Interferes with Intradermal, but Not Pulmonary, Immunization against Tuberculosis","volume":"12","author":"Price","year":"2016","journal-title":"PloS Pathog"},{"key":"B120","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2015.02.015","article-title":"Predicting vaccine responsiveness","volume":"17","author":"Boyd","year":"2015","journal-title":"Cell Host Microbe"},{"key":"B121","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","article-title":"Variation in the human immune system is largely driven by non-herita ble influences","volume":"160","author":"Brodin","year":"2015","journal-title":"Cell."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv757","article-title":"Major loci on chromosomes 8q and 3q control interferon \u03b3 Production triggered by bacillus calmette-guerin and 6-kDa early secretory antigen target, respectively, in various populations","volume":"213","author":"Jabot-Hanin","year":"2016","journal-title":"J Infect Dis"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01516-16","article-title":"Tuberculosis susceptibility and vaccine protection are independently controlled by host genotype","volume":"7","author":"Smith","year":"2016","journal-title":"MBio"},{"key":"B124","doi-asserted-by":"crossref","first-page":"100895","DOI":"10.1016\/S2666-5247(24)00127-7","article-title":"Implications of subclinical tuberculosis for vaccine trial design and global effect","volume":"5","author":"Churchyard","year":"2024","journal-title":"Lancet Microbe"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00894","article-title":"Vaccination Enhances Inhibition of Mycobacterial Growth ex vivo and Induces a Shift of Monocyte Phenotype in Mice","volume":"10","author":"Prabowo","year":"2019","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1677868","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1608104\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T12:21:01Z","timestamp":1756124461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1608104\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":125,"alternative-id":["10.3389\/fimmu.2025.1608104"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1608104","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"article-number":"1608104"}}